Literature DB >> 2582066

Seroepidemiological studies of group B Streptococcus type II.

B M Gray, D G Pritchard, H C Dillon.   

Abstract

In the course of prospective epidemiological studies of group B streptococcal (GBS) colonization and infection, we surveyed 401 paired maternal and cord sera (obtained at delivery) and 23 sera from patients with systemic type II infection for IgG antibody to GBS type II. Type II carriers were more likely to have antibody (greater than 2 micrograms/ml) than were those carrying other GBS types, whereas noncolonized patients were the least likely to have antibody. The overall prevalence of levels of antibody greater than 2 micrograms/ml was estimated to be approximately 6%, on the basis of assay results of the 401 maternal-cord pairs and adjusted for known-colonization status for the entire population of 8,928 deliveries that occurred during the study period. The majority of patients with infection had antibody levels less than 2 micrograms/ml. Five patients, however, had antibody present at levels ranging from 2.7 to 5.8 micrograms/ml. These findings suggest that "antibody deficiency" was widespread and was not by itself a useful determinant of risk for disease caused by GBS type II.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2582066     DOI: 10.1093/infdis/151.6.1073

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Prevalence of group B streptococcal type VI capsular IgG antibodies in Japan.

Authors:  K Matsubara; K Katayama; K Baba; H Nigami; H Harigaya
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-24       Impact factor: 3.267

2.  Seroepidemiology of group B Streptococcus type II antibody specificity.

Authors:  B M Gray; D G Pritchard; J D Springfield; R J Benak; H C Dillon
Journal:  Epidemiol Infect       Date:  1988-10       Impact factor: 2.451

3.  Adherence to, invasion by, and cytokine production in response to serotype VIII group B Streptococci.

Authors:  Hiroshige Mikamo; Atul K Johri; Lawrence C Paoletti; Lawrence C Madoff; Andrew B Onderdonk
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

Review 4.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

5.  Control of neonatal group B streptococcal infection.

Authors:  R W Steele
Journal:  J R Soc Med       Date:  1993-12       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.